Study guide
18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients
Key Takeaways Explain This Topic AI
The 2023 AGS Beers Criteria advise avoiding first-generation antihistamines, benzodiazepines, Z-drugs and skeletal muscle relaxants in older adults because they cause delirium and falls.
In obesity, succinylcholine is dosed on total body weight, rocuronium on ideal body weight, and induction agents such as propofol on lean body weight.
4F-PCC (Kcentra) dosing for warfarin reversal uses actual weight capped at 100 kg, so the maximum is 2,500, 3,500 or 5,000 units depending on the INR.
FDA advises avoiding NSAIDs from 20 weeks of pregnancy because of fetal kidney dysfunction and oligohydramnios, and ACE inhibitors and ARBs are fetotoxic in the second and third trimesters.
Ritonavir and cobicistat strongly inhibit CYP3A4, so oral midazolam, simvastatin and inhaled fluticasone are hazardous with boosted HIV regimens; lorazepam avoids the interaction.
Last updated: October 2026
18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients
Note
Exam scope: 2025 outline subtopic 2A6 (Considerations for Special Populations: age groups, extremes of weight, pregnancy and lactation, critical illness, immunocompromised patients). Pediatric emergencies are covered in Section 13.1, obstetric emergencies in Section 13.3, and pharmacokinetics in critical illness in Section 1.3.
Older Adults
Older adults make up a growing share of ED visits. They have less physiologic reserve, more medications and more adverse drug events. ACEP's Geriatric Emergency Department Accreditation program encourages medication review as a standard part of ED care.
Key 2023 AGS Beers Criteria for ED Prescribing
Avoid or use with caution Reason Preferred approach
First-generation antihistamines (diphenhydramine, hydroxyzine, promethazine) Anticholinergic: delirium, retention, constipation Second-generation antihistamines; non-drug sleep measures
Benzodiazepines and Z-drugs Delirium, falls, fractures, motor vehicle crashes Avoid except for alcohol or benzodiazepine withdrawal or seizures
Skeletal muscle relaxants (cyclobenzaprine, methocarbamol) Anticholinergic effects, sedation, weak evidence Heat, acetaminophen, topical NSAIDs
Meperidine Neurotoxic metabolite; poor oral efficacy Other opioids at reduced doses
Chronic NSAIDs, especially with anticoagulants or CKD GI bleeding, kidney injury, heart failure Short courses with gastroprotection, or topical NSAIDs
- Sliding-scale insulin alone Hypoglycemia without benefit Basal or basal-bolus regimens
- Sulfonylureas Prolonged hypoglycemia Other agents; glipizide if one must be used
Warfarin as initial therapy ; rivaroxaban for long-term AF or VTE Higher bleeding risk than alternatives Apixaban is generally preferred
Nitrofurantoin when CrCl is below 30 mL/min Ineffective and toxic Another agent based on culture
Antipsychotics for behavioral symptoms of dementia Boxed warning for higher mortality and stroke risk Non-drug measures; use only for danger to self or others
Kidney Function and Dosing
Serum creatinine falls with muscle mass, so a "normal" creatinine in a frail older adult can hide a CrCl of 30 mL/min. Use the Cockcroft-Gault estimate for renally cleared drugs: CrCl = [(140 − age) × weight] ÷ (72 × serum creatinine), × 0.85 for women. "Start low, go slow" applies to sedatives, opioids and antihypertensives.
Extremes of Body Weight
- Weight term Definition
- Total body weight (TBW) Actual measured weight
- Ideal body weight (IBW, Devine) Men 50 kg, women 45.5 kg, + 2.3 kg per inch over 5 feet
- Adjusted body weight (AdjBW) IBW + 0.4 × (TBW − IBW)
- Lean body weight (LBW) Fat-free mass, calculated from height, weight and sex
- Dosing Weight for Common ED Drugs in Obesity
- Drug Dosing weight and caps
- Succinylcholine TBW (plasma cholinesterase activity rises with body size)
- Rocuronium IBW (TBW dosing prolongs paralysis without a meaningful speed benefit)
- Propofol, etomidate (induction) LBW; reduce further in shock
- Vancomycin loading dose TBW, 20 to 35 mg/kg (maximum 3 g) ; maintenance by AUC monitoring
- Aminoglycosides AdjBW
- Enoxaparin treatment dose TBW at 1 mg/kg every 12 hours; check anti-Xa levels above about 150 kg
- Alteplase for stroke 0.9 mg/kg, maximum 90 mg
- Tenecteplase for stroke 0.25 mg/kg, maximum 25 mg
4F-PCC (Kcentra) for warfarin reversal Actual weight capped at 100 kg : INR 2 to below 4 → 25 units/kg (max 2,500); INR 4 to 6 → 35 units/kg (max 3,500); INR above 6 → 50 units/kg (max 5,000)
Underweight patients: when actual weight is below IBW, use actual weight. In patients with low muscle mass, both creatinine-based kidney estimates and fixed doses need care.
After bariatric surgery: avoid NSAIDs (they cause marginal ulcers) and extended-release products (absorption is unpredictable), and expect altered oral absorption.
- Pregnancy
- Physiology That Changes Dosing
Plasma volume and volume of distribution increase.
Glomerular filtration rises by about 50% , lowering levels of renally cleared drugs such as levetiracetam and enoxaparin.
CYP3A4, CYP2D6 and CYP2C9 activity increases while CYP1A2 decreases. Lamotrigine levels fall sharply because glucuronidation increases.
Albumin falls, raising the free fraction of highly bound drugs.
Labeling
The FDA Pregnancy and Lactation Labeling Rule (PLLR) , effective 2015, removed the A, B, C, D and X letter categories. Labels now give narrative risk summaries in section 8.1 (Pregnancy), 8.2 (Lactation) and 8.3 (Females and Males of Reproductive Potential).
Emergency Drug Choices in Pregnancy
Do not withhold needed treatment. Resuscitation drugs, RSI agents, epinephrine for anaphylaxis, CT pulmonary angiography with contrast and standard ACLS doses are all appropriate. The mother's survival is the fetus's best protection.
Generally acceptable Avoid or use only with specialist input
Acetaminophen NSAIDs from 20 weeks (FDA 2020: fetal kidney dysfunction, oligohydramnios; ductal closure later in pregnancy)
Penicillins, cephalosporins, azithromycin ACE inhibitors and ARBs (fetotoxic in the second and third trimesters)
LMWH (preferred anticoagulant) Warfarin (embryopathy; used only for mechanical valves under specialist care); DOACs (too little data)
Labetalol, nifedipine, hydralazine (Section 13.3) Valproate (neural tube defects, lower IQ); carbamazepine and phenytoin (malformations)
Insulin Tetracyclines in the second and third trimesters; fluoroquinolones unless there is no alternative
Metoclopramide, ondansetron (after counseling) for nausea Isotretinoin, methotrexate, misoprostol (outside obstetric use)
In September 2025 FDA began a labeling change about a possible association between acetaminophen use in pregnancy and neurodevelopmental conditions. ACOG and SMFM responded that acetaminophen remains appropriate when it is needed for pain or fever, since untreated fever also carries risk. Use the lowest effective dose for the shortest time.
Rh(D) immune globulin: for bleeding, trauma or pregnancy loss in Rh-negative patients, follow current ACOG guidance. ACOG's 2024 update says it can be forgone for abortion or pregnancy loss before 12 weeks. Later in pregnancy, the standard dose is 300 mcg within 72 hours.
Lactation
Most ED medications are compatible with breastfeeding. Check LactMed , the free NIH database.
Avoid codeine and tramadol (FDA), and use the lowest effective opioid doses for short courses.
After procedural sedation or anesthesia, the patient can resume breastfeeding once alert ; pumping and discarding milk is generally unnecessary.
Breastfeeding does not need to be interrupted after iodinated or gadolinium contrast (ACR).
- Immunocompromised Patients
- Solid Organ Transplant Recipients
Do not stop immunosuppressants without speaking to the transplant team.
Tacrolimus and cyclosporine interact with azoles, macrolides, diltiazem, verapamil and nirmatrelvir-ritonavir (all raise levels and toxicity) and with rifampin (which lowers levels and risks rejection). Calcineurin inhibitors also cause nephrotoxicity, hyperkalemia and hypomagnesemia.
Keep PJP prophylaxis (usually trimethoprim-sulfamethoxazole) and expect atypical, opportunistic infections with blunted fever.
People Living With HIV
Ritonavir- or cobicistat-boosted regimens strongly inhibit CYP3A4:
Oral midazolam and triazolam are contraindicated. Lorazepam, which is glucuronidated, is a safer anxiolytic.
Simvastatin and lovastatin are contraindicated.
Inhaled or intranasal fluticasone and budesonide can cause Cushing syndrome and adrenal suppression.
Fentanyl, oxycodone, DOACs and some calcium channel blockers need dose reduction or another drug.
Integrase inhibitors chelate with antacids and other divalent cations, so separate the doses. Never stop antiretroviral therapy just because the patient has been admitted.
Asplenia and Chronic Corticosteroid Use
Asplenia: fever is an emergency because of the risk of overwhelming infection from encapsulated organisms. Give ceftriaxone (plus vancomycin where resistant pneumococcus is a concern) within an hour .
Chronic corticosteroids: prednisone of about 20 mg/day or more for 3 weeks or longer can suppress the adrenal axis. Give stress-dose hydrocortisone 100 mg IV for shock or major stress (Section 11.3).
Biologics such as TNF inhibitors and JAK inhibitors raise the risk of TB, fungal and opportunistic infections. Live vaccines are contraindicated ; tetanus toxoid is not a live vaccine.
Febrile neutropenia is covered in Section 17.3.